38
Participants
Start Date
March 15, 2017
Primary Completion Date
May 11, 2020
Study Completion Date
May 11, 2020
S64315 once a week
S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
S64315 twice a week
S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
The Alfred Hospital Department of Haematology, Melbourne
Royal Melbourne Hospital, Department of Clinical Haematology and BMT Service, Melbourne
Institut Paoli-Calmettes Departement d'Hématologie, Marseille
Hospital Universitario La Fe Hematology Department, Valencia
Hôpital Saint-Antoine Département d'Hematologie Clinique et de Thérapie cellulaire, Paris
The University of Texas MD Anderson Cancer Center, Department of Leukemia, Division of Cancer Medicine, Houston
Patient Care Location: Smilow Cancer Hospital at Yale, New Haven
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse
Hospital Universitario Vall d' Hebron/VHIO Hematology Department, Barcelona
ADIR, a Servier Group company
INDUSTRY
Institut de Recherches Internationales Servier
OTHER